Pralatrexate
From Wikipedia, the free encyclopedia
 |
This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (June 2007) |
 |
|
|
Pralatrexate
|
|
| Systematic (IUPAC) name | |
| N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl] -3-butynyl]benzoyl]-L-glutamic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C23H23N7O5 |
| Mol. mass | 477.47 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Pralatrexate (rINN), also known as 10-propargyl-10-deazaaminopterin, common name PDX, is a drug candidate being studied for the treatment of cancer. PDX is a folate analog inhibitor of dihydrofolate reductase. As of July 2005, it is undergoing Phase 1 and Phase 2 clinical trials for treatment of non-Hodgkin lymphoma and non-small cell lung cancer.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
